Eurocor GmbH announces Study results of Valentines Trial I

Date: 2011/03/04

DIOR® shows effective and safe treatment for cases of In-Stent Restenosis (ISR)
Database with larges group of patients ever enrolled to show effectiveness of DEB in treatmen of ISR

Eurocor GmbH, the Bonn-based subsidiary of Opto Circuits (India) Ltd; presented the first eight month follow-up data from the Valentines Trial I Global Registry on March 1st 2011 during the CRT 2011 Meeting. Eurocor's groundbreaking Valentines Trial I was conducted with an objective to assess the efficacy of the paclitaxel-eluting balloon Dior®- II far In-stent Restenosis (ISR) following Bare Metal Stent (BMS) and Drug-eluting Stent (DES) implantation at 6-9 months. 300 patients (those suffering from ISR) were enrolled by 96 Investigators from 26 countries starting 14th February 2010 in aperiod of 9 days and the initial eight-month foIlow-up data was announced Tuesday by principal investigator Prof. Dr. Sigmund Silber of Munich, Germany during the Conference. This landmark clinical study represents the largest group of patients ever enrolled in a study on the effectiveness of DEB in the treatment of ISR.

Eurocor GmbH announces Study results of Valentines Trial I (English)

Eurocor GmbH veröffentlich Studienergebnisse zu Valentines Trial I (Deutsch)